Skip to main content
Erschienen in: Clinical Rheumatology 1/2016

01.01.2016 | Brief Report

The association between serious infection and disease outcome in patients with rheumatoid arthritis

verfasst von: Mikiko Iguchi-Hashimoto, Motomu Hashimoto, Takao Fujii, Masahide Hamaguchi, Moritoshi Furu, Masahiro Ishikawa, Hiromu Ito, Noriyuki Yamakawa, Chikashi Terao, Keiichi Yamamoto, Wataru Yamamoto, Koichiro Ohmura, Tsuneyo Mimori

Erschienen in: Clinical Rheumatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to study the association between the past history of serious infection (SI) that required hospitalization and the current disease status of rheumatoid arthritis (RA), including disease activity, physical disability, and radiological joint destruction. The history of hospitalized infection was retrospectively analyzed in a cohort of 370 RA patients. The patients were divided into three groups based on the number of SI events (SI = 0, SI = 1, SI ≥ 2). Disease activity score using 28 joints (DAS28), Health Assessment Questionnaire (HAQ), and modified total sharp score (mTSS) adjusted after disease duration or other confounding factors were compared among the three groups. Among the study patients, 7.3 % (27 patients) experienced single SI (SI = 1) and 2.1 % (8 patients) experienced multiple SI events (SI ≥ 2). Compared with patients with no SI (SI = 0), patients with SI (SI = 1 or SI ≥ 2) had increased pulmonary and autoimmune comorbidities and were more frequently treated with glucocorticoids. DAS28 was not different among the groups, while HAQ and mTSS increased with the number of SI. After adjustment, only mTSS adjusted after disease duration remained statistically significantly different between patients with SI = 0 and SI ≥ 2 (p = 0.030). Multiple SI events are associated with advanced physical disability and radiological joint destruction in patients with RA.
Literatur
2.
Zurück zum Zitat Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594–1602. doi:10.1056/nejm200011303432202 PubMedCrossRef Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594–1602. doi:10.​1056/​nejm200011303432​202 PubMedCrossRef
3.
Zurück zum Zitat van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeek D, Wajdula J, Fatenejad S (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and rheumatism 56(12):3928–3939. doi:10.1002/art.23141 PubMedCrossRef van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeek D, Wajdula J, Fatenejad S (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and rheumatism 56(12):3928–3939. doi:10.​1002/​art.​23141 PubMedCrossRef
4.
Zurück zum Zitat Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12(2):225–229. doi:10.1016/j.autrev.2012.06.008 PubMedCrossRef Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12(2):225–229. doi:10.​1016/​j.​autrev.​2012.​06.​008 PubMedCrossRef
5.
Zurück zum Zitat Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38(7):1258–1264. doi:10.3899/jrheum.101009 PubMedCrossRef Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38(7):1258–1264. doi:10.​3899/​jrheum.​101009 PubMedCrossRef
6.
Zurück zum Zitat Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and rheumatism 52(11):3403–3412. doi:10.1002/art.21386 PubMedCrossRef Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and rheumatism 52(11):3403–3412. doi:10.​1002/​art.​21386 PubMedCrossRef
7.
Zurück zum Zitat Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M (2012) Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(8):1125–1134. doi:10.1002/acr.21666 Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M (2012) Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(8):1125–1134. doi:10.​1002/​acr.​21666
8.
Zurück zum Zitat Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66(10):1339–1344. doi:10.1136/ard.2006.062760 PubMedPubMedCentralCrossRef Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66(10):1339–1344. doi:10.​1136/​ard.​2006.​062760 PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E (2011) The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70(8):1401–1406. doi:10.1136/ard.2010.146365 PubMedPubMedCentralCrossRef Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E (2011) The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70(8):1401–1406. doi:10.​1136/​ard.​2010.​146365 PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C (2013) Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 65(3):353–361. doi:10.1002/acr.21812 CrossRef Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C (2013) Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 65(3):353–361. doi:10.​1002/​acr.​21812 CrossRef
12.
Zurück zum Zitat Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis and rheumatism 62(9):2625–2632. doi:10.1002/art.27555 PubMedCrossRef Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis and rheumatism 62(9):2625–2632. doi:10.​1002/​art.​27555 PubMedCrossRef
13.
Zurück zum Zitat Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69(2):380–386. doi:10.1136/ard.2008.089276 PubMedPubMedCentralCrossRef Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69(2):380–386. doi:10.​1136/​ard.​2008.​089276 PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T (2013) Three groups in the 28 joints for rheumatoid arthritis synovitis—analysis using more than 17,000 assessments in the KURAMA database. PLoS One 8(3):e59341. doi:10.1371/journal.pone.0059341 PubMedPubMedCentralCrossRef Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T (2013) Three groups in the 28 joints for rheumatoid arthritis synovitis—analysis using more than 17,000 assessments in the KURAMA database. PLoS One 8(3):e59341. doi:10.​1371/​journal.​pone.​0059341 PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Furu M, Hashimoto M, Ito H, Fujii T, Terao C, Yamakawa N, Yoshitomi H, Ogino H, Ishikawa M, Matsuda S, Mimori T (2014) Discordance and accordance between patient’s and physician’s assessments in rheumatoid arthritis. Scand J Rheumatol 43(4):291–295. doi:10.3109/03009742.2013.869831 PubMedCrossRef Furu M, Hashimoto M, Ito H, Fujii T, Terao C, Yamakawa N, Yoshitomi H, Ogino H, Ishikawa M, Matsuda S, Mimori T (2014) Discordance and accordance between patient’s and physician’s assessments in rheumatoid arthritis. Scand J Rheumatol 43(4):291–295. doi:10.​3109/​03009742.​2013.​869831 PubMedCrossRef
17.
18.
Zurück zum Zitat Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 71(7):1128–1133. doi:10.1136/annrheumdis-2011-200702 PubMedPubMedCentralCrossRef Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 71(7):1128–1133. doi:10.​1136/​annrheumdis-2011-200702 PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and rheumatism 54(2):628–634. doi:10.1002/art.21568 PubMedCrossRef Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and rheumatism 54(2):628–634. doi:10.​1002/​art.​21568 PubMedCrossRef
20.
Zurück zum Zitat Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62(8):722–727PubMedPubMedCentralCrossRef Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62(8):722–727PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis and rheumatism 62(6):1583–1591. doi:10.1002/art.27405 PubMedPubMedCentralCrossRef Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis and rheumatism 62(6):1583–1591. doi:10.​1002/​art.​27405 PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL, Bongartz T (2013) Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 65(8):1243–1250. doi:10.1002/acr.21986 CrossRef Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL, Bongartz T (2013) Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 65(8):1243–1250. doi:10.​1002/​acr.​21986 CrossRef
23.
Zurück zum Zitat Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and rheumatism 59(6):762–784. doi:10.1002/art.23721 PubMedCrossRef Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and rheumatism 59(6):762–784. doi:10.​1002/​art.​23721 PubMedCrossRef
24.
Zurück zum Zitat Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis and rheumatism 50(1):36–42. doi:10.1002/art.11481 PubMedCrossRef Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis and rheumatism 50(1):36–42. doi:10.​1002/​art.​11481 PubMedCrossRef
Metadaten
Titel
The association between serious infection and disease outcome in patients with rheumatoid arthritis
verfasst von
Mikiko Iguchi-Hashimoto
Motomu Hashimoto
Takao Fujii
Masahide Hamaguchi
Moritoshi Furu
Masahiro Ishikawa
Hiromu Ito
Noriyuki Yamakawa
Chikashi Terao
Keiichi Yamamoto
Wataru Yamamoto
Koichiro Ohmura
Tsuneyo Mimori
Publikationsdatum
01.01.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 1/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-3143-3

Weitere Artikel der Ausgabe 1/2016

Clinical Rheumatology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.